Comparison of risk stratification in patients with DLBCL by the traditional IPI and adjusted IPI scores. (A) Risk stratification of DLBCL groups by the traditional IPI. (B) Risk stratification of DLBCL by the M-IPI-R, defined by each patient’s IPI score plus risk scores for CD37 status (CD37⁺, 0; CD37⁻, 1 or 2 as indicated) and GCB/ABC cell of origin (GCB, 0; ABC, 1). (C) Risk stratification of DLBCL by the IPI+IHC, defined by each patient’s IPI score plus risk scores for CD37 status (CD37⁺, 0; CD37⁻, 3), and Myc and Bcl-2 protein levels (low [IHC <70%], 0; high [IHC ≥70%], 1).